Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All vitamin D studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchVitamin DVitamin D (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality, D3 33% Improvement Relative Risk Mortality, D2 24% Case, D3 20% Case, D2 28% Vitamin D for COVID-19  Gibbons et al.  Prophylaxis Is prophylaxis with vitamin D beneficial for COVID-19? PSM retrospective 398,996 patients in the USA Lower mortality (p<0.0001) and fewer cases (p<0.0001) c19early.org Gibbons et al., Scientific Reports, Nov 2022 Favors vitamin D Favors control

Association between vitamin D supplementation and COVID-19 infection and mortality

Gibbons et al., Scientific Reports, doi:10.1038/s41598-022-24053-4
Nov 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Vitamin D for COVID-19
8th treatment shown to reduce risk in October 2020
 
*, now known with p < 0.00000000001 from 120 studies, recognized in 8 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
PSM retrospective in the USA, showing lower COVID-19 mortality and cases with vitamin D prophylaxis.
This is the 101st of 120 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 248 sextillion).
29 studies are RCTs, which show efficacy with p=0.0000024.
risk of death, 33.3% lower, HR 0.67, p < 0.001, treatment 5,315 of 199,498 (2.7%), control 6,591 of 199,498 (3.3%), D3, propensity score matching, Cox proportional hazards.
risk of death, 23.5% lower, HR 0.77, p = 0.10, treatment 716 of 33,216 (2.2%), control 987 of 33,216 (3.0%), NNT 123, D2, propensity score matching, Cox proportional hazards.
risk of case, 20.3% lower, HR 0.80, p < 0.001, treatment 462 of 199,498 (0.2%), control 689 of 199,498 (0.3%), D3, propensity score matching, Cox proportional hazards.
risk of case, 28.0% lower, HR 0.72, p < 0.001, treatment 65 of 33,216 (0.2%), control 86 of 33,216 (0.3%), NNT 1582, D2, propensity score matching, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gibbons et al., 12 Nov 2022, retrospective, USA, peer-reviewed, 7 authors, dosage varies. Contact: jgibbo13@jhu.edu.
This PaperVitamin DAll
Association between vitamin D supplementation and COVID-19 infection and mortality
Jason B Gibbons, Edward C Norton, Jeffrey S Mccullough, David O Meltzer, Jill Lavigne, Virginia C Fiedler, Robert D Gibbons
Scientific Reports, doi:10.1038/s41598-022-24053-4
Vitamin D deficiency has long been associated with reduced immune function that can lead to viral infection. Several studies have shown that Vitamin D deficiency is associated with increases the risk of infection with COVID-19. However, it is unknown if treatment with Vitamin D can reduce the associated risk of COVID-19 infection, which is the focus of this study. In the population of US veterans, we show that Vitamin D 2 and D 3 fills were associated with reductions in COVID-19 infection of 28% and 20%, respectively [(D 3 Hazard Ratio (HR) = 0.80, [95% CI 0.77, 0.83]), D 2 HR = 0.72, [95% CI 0.65, 0.79]]. Mortality within 30-days of COVID-19 infection was similarly 33% lower with Vitamin D 3 and 25% lower with D 2 (D 3 HR = 0.67, [95% CI 0.59, 0.75]; D 2 HR = 0.75, [95% CI 0.55, 1.04]). We also find that after controlling for vitamin D blood levels, veterans receiving higher dosages of Vitamin D obtained greater benefits from supplementation than veterans receiving lower dosages. Veterans with Vitamin D blood levels between 0 and 19 ng/ml exhibited the largest decrease in COVID-19 infection following supplementation. Black veterans received greater associated COVID-19 risk reductions with supplementation than White veterans. As a safe, widely available, and affordable treatment, Vitamin D may help to reduce the severity of the COVID-19 pandemic. Vitamin D insufficiency and deficiency affect approximately half of the US population, with increased rates in people with darker skin, reduced sun exposure, people living in higher latitudes in the winter, nursing home residents, and healthcare workers 1 . Populations with low levels of Vitamin D have also experienced higher rates of COVID-19 [2] [3] [4] [5] [6] . Despite several studies pointing to an association between low levels of vitamin D and COVID-19 2-7 , limited information is available regarding the potential for supplementation with vitamin D to reduce the risk of COVID-19 infection. Expanding supplementation with vitamin D may present a new and unique opportunity to mitigate global infection rates, given that it is a widely available over-the-counter (OTC), inexpensive, and is associated with relatively few side effects. We conducted a large-scale pharmacoepidemiologic study of the association between vitamin D 3 and D 2 supplementation and the probability of COVID-19 infection and COVID-19 infection ending in mortality within 30-days in the Department of Veterans Administration (VA) in the United States. We also studied whether patient sex, race, vitamin D serum levels, and cumulative D 3 supplementation dosage modified the association.
Author contributions J.G. Wrote the manuscript, analyzed the data, planned the analysis, and reviewed the manuscript. E.N. planned the analysis and reviewed the manuscript. J.M. planned the analysis and reviewed the manuscript. D.M. planned the analysis and reviewed the manuscript. J.L. planned the analysis and reviewed the manuscript and obtained the data. V.F.. planned the analysis and reviewed the manuscript. R.G. Wrote the manuscript, planned the analysis, and reviewed the manuscript. Competing interests Dr. DO Meltzer reported grants from the National Institutes of Health during the conduct of the study. Dr. JB Gibbons, Dr. J Lavigne, Dr. VC Fiedler, Dr. EC Norton, Dr. J McCullough, Dr. RD Gibbons have no conflicts to report. Additional information Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-24053-4. Correspondence and requests for materials should be addressed to J.B.G. Reprints and permissions information is available at www.nature.com/reprints. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Akbar, Wibowo, Pranata, Setiabudiawan, Low serum 25-hydroxyvitamin D (Vitamin D) level is associated with susceptibility to COVID-19, severity, and mortality: A systematic review and meta-analysis, Front. Nutr
Break, Aberrant type 1 immunity drives susceptibility to mucosal fungal infections, Science
Cardone, Complement regulator CD46 temporally regulates cytokine production by conventional and unconventional T cells, Nat. Immunol
Castillo, Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study, J. Steroid Biochem. Mol. Biol, doi:10.1016/j.jsbmb.2020.105751
Chauss, Autocrine Vitamin D signaling switches off pro-inflammatory programs of TH1 cells, Nat. Immunol, doi:10.1038/s41590-021-01080-3
Chen, Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: A meta-analysis and GRADE assessment of cohort studies and RCTs, Nutr. J, doi:10.1186/s12937-021-00744-y
Chiodini, Vitamin D status and SARS-CoV-2 infection and COVID-19 clinical outcomes, Front. Public Health, doi:10.3389/fpubh.2021.736665
Dror, Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness, PLoS ONE, doi:10.1371/journal.pone.0263069
Forrest, Stuhldreher, Prevalence and correlates of vitamin D deficiency in US adults, Nutr. Res, doi:10.1016/j.nutres.2010.12.001
Gazzinelli, In the absence of endogenous IL10, mice acutely infected with Toxoplasma gondii succumb to a lethal immune response dependent on CD4+ T cells and accomplished by overproduction of IL12, IFN gamma and TNF alpha, J. Immunol
Grove, Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review, BMJ Open, doi:10.1136/bmjopen-2020-043737
Israel, Assi Cicurel, Feldhamer, Dror, Giveon et al., The link between vitamin D deficiency and COVID-19 in a large population, doi:10.1101/2020.09.04.20188268
Kaufman, Niles, Kroll, Bi, Holick, SARS-CoV-2 positivity rates associated with circulating 25-hydroxyvitamin D levels, PLoS ONE, doi:10.1371/journal.pone.0239252
Loucera, Real world evidence of calcifediol or vitamin D prescription and mortality rate of COVID-19 in a retrospective cohort of hospitalized Andalusian patients, Sci. Rep, doi:10.1038/s41598-021-02701-5
Lucas, Longitudinal analyses reveal immunological misfiring in severe COVID-19, Nature
Maghbooli, Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection, PLoS ONE, doi:10.1371/journal.pone.0239799
Martineau, Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data, BMJ, doi:10.1136/bmj.i6583
Martín Giménez, Vitamin D deficiency in African Americans is associated with a high risk of severe disease and mortality by SARS-CoV-2, J. Hum. Hypertens, doi:10.1038/s41371-020-00398-z
Meltzer, Association of vitamin D status and other clinical characteristics with COVID-19 test results, JAMA Netw. Open, doi:10.1001/jamanetworkopen.2020.19722
Meltzer, Best, Schram, Solway, Comment On Murai et al., Reanalysis suggests vitamin D decreased intensive care and mechanical ventilation use, JAMA
Meltzer, Best, Vokes, Association of vitamin D levels, race/ethnicity, and clinical characteristics with COVID-19 test results, JAMA Netw. Open, doi:10.1001/jamanetworkopen.2021.4117
Merzon, Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection: An Israeli population-based study, FEBS J, doi:10.1111/febs.15495
Murai, Effect of a single high dose of vitamin D3 on hospital length of stay in patients with moderate to severe COVID-19: A randomized clinical trial, JAMA, doi:10.1001/jama.2020.26848
Richie, Ortiz-Ospina, Beltekian, Mathieu, Hassel et al., Statistics and research-Coronavirus pandemic (COVID-19)
Sanghera, Sapkota, Aston, Blackett, Vitamin D status, gender differences, and cardiometabolic health disparities, Ann. Nutr. Metab, doi:10.1159/000458765
Sinkovits, Complement overactivation and consumption predicts in-hospital mortality in SARS-CoV-2 infection, Front. Immunol
Stroehlein, Vitamin D supplementation for the treatment of COVID-19: A living systematic review, Cochrane Database Syst. Rev, doi:10.1002/14651858.CD015043
West, Kolev, Kemper, Complement and the regulation of T cell responses, Annu. Rev. Immunol
Yan, SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation, Scientific Reports
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit